AstraZeneca (LON:AZN)‘s stock had its “hold” rating reaffirmed by equities researchers at Liberum Capital in a report issued on Monday. They currently have a GBX 5,000 ($69.08) price target on the biopharmaceutical company’s stock. Liberum Capital’s price objective suggests a potential upside of 4.17% from the company’s previous close.
Several other research analysts also recently commented on AZN. HSBC increased their price objective on AstraZeneca from GBX 4,340 ($59.96) to GBX 4,380 ($60.51) and gave the company a “reduce” rating in a research note on Thursday, November 16th. Jefferies Group reissued a “hold” rating and issued a GBX 5,100 ($70.46) price objective on shares of AstraZeneca in a research note on Thursday, November 16th. JPMorgan Chase & Co. set a GBX 4,800 ($66.32) price objective on AstraZeneca and gave the company a “neutral” rating in a research note on Thursday, November 30th. Morgan Stanley reissued an “equal weight” rating and issued a GBX 5,000 ($69.08) price objective on shares of AstraZeneca in a research note on Friday, December 1st. Finally, Shore Capital reissued a “hold” rating on shares of AstraZeneca in a research note on Monday, December 4th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of GBX 5,199.70 ($71.84).
AstraZeneca (LON AZN) traded up GBX 14.50 ($0.20) during midday trading on Monday, reaching GBX 4,800 ($66.32). The company had a trading volume of 1,664,175 shares, compared to its average volume of 2,300,000. AstraZeneca has a 1 year low of GBX 4,260 ($58.86) and a 1 year high of GBX 5,520 ($76.26). The firm has a market cap of $60,790.00 and a P/E ratio of 2,823.53.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.